NCT06974812

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Study of IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.

Conditions

• Unresectable Locally Advanced or Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	IBI3014	12 mg/kg D1 IV Q3W
DRUG	IBI3014	6 mg/kg D1 IV Q3W
DRUG	IBI3014	1 mg/kg D1 IV Q3W
DRUG	IBI3014	15 mg/kg D1 IV Q3W
DRUG	IBI3014	9 mg/kg D1 IV Q3W
DRUG	IBI3014	3 mg/kg D1 IV Q3W
DRUG	IBI3014	20 mg/kg D1 IV Q3W
DRUG	IBI3014	18 mg/kg D1 IV Q3W

Timeline

• Start date: 2025-04-18
• Primary completion: 2026-06-30
• Completion: 2027-06-30
• First posted: 2025-05-16
• Last updated: 2026-01-29

Locations

3 sites across 1 country: China